Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Cancer development and chemo-resistance are often due to impaired functioning of the p53 tumor suppressor through genetic mutation or sequestration by other proteins. In glioblastoma multiforme (GBM), p53 availability is frequently reduced because it binds to the Murine Double Minute-2 (MDM2) oncoprotein, which accumulates at high concentrations in tumor cells. The use of MDM2 inhibitors that interfere with the binding of p53 and MDM2 has become a valid approach to inhibit cell growth in a number of cancers; however little is known about the efficacy of these inhibitors in GBM. We report that a new small-molecule inhibitor of MDM2 with a spirooxoindolepyrrolidine core structure, named ISA27, effectively reactivated p53 function and inhibited human GBM cell growth in vitro by inducing cell cycle arrest and apoptosis. In immunoincompetent BALB/c nude mice bearing a human GBM xenograft, the administration of ISA27 in vivo activated p53, inhibited cell proliferation and induced apoptosis in tumor tissue. Significantly, ISA27 was non-toxic in an in vitro normal human cell model and an in vivo mouse model. ISA27 administration in combination with temozolomide (TMZ) produced a synergistic inhibitory effect on GBM cell viability in vitro, suggesting the possibility of lowering the dose of TMZ used in the treatment of GBM. In conclusion, our data show that ISA27 releases the powerful antitumor capacities of p53 in GBM cells. The use of this MDM2 inhibitor could become a novel therapy for the treatment of GBM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Costa et al. demonstrated that TMZ synergized with the MDM2 PPI inhibitor ISA27 to kill U87-MG cells in vitro”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An increase in p53 expression (but not p21 nor MDM2) was observed in tumors at relapse, potentially associated with the emergence of TP53 mutant tumor cell subpopulations, as it was reported previously (reviewed in [36]).”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Although it has been shown that nutlin3a and other MDM2 PPI inhibitors have single-agent activity in inhibiting the growth of a variety of tumor types including GBM”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
In the citing paper
“and administration of ISA27 alone inhibited growth of GBM flank xenografts.13”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“The cytosolic protein content was determined as previously described [36], and the cytochrome C content was determined using the Platinum Human Cytochrome C ELISA.”
MethodIsolation of mononuclear cells and granulocytes from human blood.
Bøyum, A. (1968) · Scandinavian Journal of Clinical and Laboratory Investigation · Cited by 9,585
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 1×
“The senescence marker, Senescence-associated beta-galactosidase (SA-b-Gal), was detected as previously described [35], and the cells were then washed in PBS (16) and photographed at 1006 magnification.”
MethodIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 2×
“Recently, Nutlin-3, the first potent MDM2 small-molecule inhibitor identified [23], and new D-peptide derivatives [14,24] were reported to be effective at inhibiting GBM cell growth in vitro [14,24,25], suggesting the validity of this experimental approach for the treatment of GBM.”
BackgroundMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 2×
“Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor in humans, and despite technical advances in neurosurgery and clinical neuro-oncology, the prognosis for GBM patients remains very poor [1–8].”
BackgroundBerenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414 · cited 1×
“A graphical assessment of synergy with regard to growth inhibition was performed using isobolographic analysis [39,40].”
MethodGenetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · cited 1×
“Interestingly, MDM2 inhibitors have been reported to induce cancer cell apoptosis even without the concomitant application of genotoxic stimuli [17,18,20].”
Background
Research works printed but not linked: 1
- Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: De Vita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles of oncology. Philadelphia: Lippincott-Raven. 2100–2161.
Cited by
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
“As an illustration, novel MDM2 inhibitors have been reported to inhibit the growth of TP53-wild-type glioblastoma PDCLs, regardless of the tumor MDM2 amplification status [117, 118].”
BackgroundTargeting autophagy to sensitive glioma to temozolomide treatment
Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 299
“Apart from DNA repair systems, it has been demonstrated that other factors, including epidermal growth factor receptor (EGFR) [31], phosphatase and tensin homolog (PTEN) [32], galectin-1 [33], murine double minute 2 (Mdm2) [34], p53 [35], PI3K/AKT/mTOR pathway [36], and sphingosine-1-phosphate/ sphingosine kinases [37…”
BackgroundMolecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
“MDM2 and MDM4 amplifications result in p53 inactivation and MDM2 inhibition has recently emerged as a strategy to restore p53 function [139,140].”
BackgroundGlioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 157
“Most GBMs harbor recurrent molecular alterations disrupting core pathways involved in regulation of growth (EGFR [9,10], PDGFRA [11], FGFR [12,13], mitogen-activated protein kinase (MAPK) [14,15] and phosphoinositide 3-kinase (PI3K) [16,17] signaling pathways), cell cycle [18–21], autophagy [22], DNA repair, and apopt…”
BackgroundA Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
Silva, E. C. D., Mercier, M.-C., Étienne-Selloum, N., Dontenwill, M., & Choulier, L. (2021) · Cancers · doi:10.3390/cancers13081795 · Cited by 159
Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications
Valdés-Rives, S. A., Casique-Aguirre, D., Germán-Castelán, L., Velasco-Velázquez, M. A., & González-Arenas, A. (2017) · BioMed Research International · doi:10.1155/2017/7403747 · Cited by 114
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
“For example, temozolomide was previously shown to act synergistically with RG7112 (36).”
BackgroundDaniele, S., Costa, B., Zappelli, E., Pozzo, E. D., Sestito, S., Nesi, G., Campiglia, P., Marinelli, L., Novellino, E., Rapposelli, S., et al. (2015) · Scientific Reports · doi:10.1038/srep09956 · Cited by 102
Self-citationRetractedMechanisms of Cell Cycle Arrest and Apoptosis in Glioblastoma
Gousias, K., Theocharous, T., & Simon, M. (2022) · Biomedicines · doi:10.3390/biomedicines10030564 · Cited by 106
Daniele, S., Giacomelli, C., Zappelli, E., Granchi, C., Trincavelli, M. L., Minutolo, F., & Martini, C. (2015) · Scientific Reports · doi:10.1038/srep15556 · Cited by 94
Self-citationLakoma, A., Barbieri, E., Agarwal, S., Jackson, J., Chen, Z., Kim, Y., McVay, M., Shohet, J. M., & Kim, E. S. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.26 · Cited by 77
On the Concepts and History of Glioblastoma Multiforme - Morphology, Genetics and Epigenetics
Stoyanov, G. S., & Dzhenkov, D. L. (2018) · Folia Medica · doi:10.1515/folmed-2017-0069 · Cited by 96
The Citrus Flavanone Naringenin Protects Myocardial Cells against Age‐Associated Damage
Pozzo, E. D., Costa, B., Cavallini, C., Testai, L., Martelli, A., Calderone, V., & Martini, C. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9536148 · Cited by 82
“To evaluate the percentage of senescent cells 3 days after the H 2 O 2 insult, staining for the senescence marker sa-β-gal was performed as previously reported [25].”
MethodSelf-citationAntioxidant and Antisenescence Effects of Bergamot Juice
Da Pozzo, E., De Leo, M., Faraone, I., Milella, L., Cavallini, C., Piragine, E., Testai, L., Calderone, V., Pistelli, L., Braca, A., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9395804 · Cited by 75
Self-citationMolecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review
Esemen, Y., Awan, M., Parwez, R., Baig, A., Rahman, S., Masala, I., Franchini, S., & Giakoumettis, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052607 · Cited by 76
“It was also effective in inhibiting cell proliferation and inducing apoptosis of tumour tissue in mouse models [85].”
BackgroundDaniele, S., Taliani, S., Pozzo, E. D., Giacomelli, C., Costa, B., Trincavelli, M. L., Rossi, L., Pietra, V. L., Barresi, E., Carotenuto, A., et al. (2014) · Scientific Reports · doi:10.1038/srep04749 · Cited by 66
Self-citationTestai, L., Pozzo, E. D., Piano, I., Pistelli, L., Gargini, C., Breschi, M. C., Braca, A., Martini, C., Martelli, A., & Calderone, V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00071 · Cited by 72
“To evaluate the number of senescent cells after 3 days from Dox insult, the senescence marker sa-beta-Gal was detected as previously reported (Costa et al., 2013).”
MethodSelf-citationDaniele, S., Sestito, S., Pietrobono, D., Giacomelli, C., Chiellini, G., Maio, D. D., Marinelli, L., Novellino, E., Martini, C., & Rapposelli, S. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00251 · Cited by 58
Self-citationBreaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles
Miranda, A., Blanco‐Prieto, M. J., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.049 · Cited by 58
Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152513 · Cited by 49
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis
Richardson, T. E., Snuderl, M., Serrano, J., Karajannis, M. A., Heguy, A., Oliver, D., Raisanen, J. M., Maher, E. A., Pan, E., Barnett, S. L., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2431-y · Cited by 49
Forte, I. M., Indovina, P., Iannuzzi, C. A., Cirillo, D., Marzo, D. D., Barone, D., Capone, F., Pentimalli, F., & Giordano, A. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4788 · Cited by 43
“To date, different other compounds targeting the MDM2-p53 interaction have been designed, which have proven to be promising also for GB treatment (27-33,35-39).”
BackgroundMDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
“Its analogue Nutlin-3a was effective at inhibiting GB cell growth, inducing varying levels of apoptosis and senescence, decreasing TMZ resistance and acting as a radiosensitizer (88, 142).”
BackgroundIndole Alkaloids, Synthetic Dimers and Hybrids with Potential In Vivo Anticancer Activity
Song, F., Bian, Y., Liu, J., Li, Z., Zhao, L. H., Fang, J., Lai, Y.-H., & Zhou, M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200908162311 · Cited by 40
Daniele, S., Pietrobono, D., Fusi, J., Iofrida, C., Chico, L., Petrozzi, L., Gerfo, A. L., Baldacci, F., Galetta, F., Siciliano, G., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0523-5 · Cited by 47
Self-citationCholia, R. P., Dhiman, M., Kumar, R., & Mantha, A. K. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0233-3 · Cited by 40
Pozzo, E. D., Pietra, V. L., Cosimelli, B., Settimo, F. D., Giacomelli, C., Marinelli, L., Martini, C., Novellino, E., Taliani, S., & Greco, G. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn4002208 · Cited by 42
Self-citationChemical Variations on the p53 Reactivation Theme
Ribeiro, C. J. A., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2016) · Pharmaceuticals · doi:10.3390/ph9020025 · Cited by 42
“Destabilization of p53-MDM2 interaction by compound 36 was established first by NMR analysis (AIDA method) [102], and later complemented by an in depth in vitro validation in human glioblastoma multiforme [103].”
MethodGiacomelli, C., Natali, L., Trincavelli, M. L., Daniele, S., Bertoli, A., Flamini, G., Braca, A., & Martini, C. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.02.019 · Cited by 36
Self-citationTarget-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents
Salerno, S., Barresi, E., Baglini, E., Poggetti, V., Settimo, F. D., & Taliani, S. (2023) · Molecules · doi:10.3390/molecules28062587 · Cited by 33
“In this context, in 2013 a novel spirooxoindolepyrrolidine MDM2 inhibitor, 13 (Chart 5) [77], was investigated to assess its activity on human GBM cell lines [75].”
BackgroundInfluentialWei, J., Wang, Z., Wang, W., Liu, X., Wan, J., Yuan, Y., Li, X., Ma, L., & Liu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.660005 · Cited by 31
“In addition, epidermal growth factor receptor (EGFR) (Chong et al., 2015), murine double minute 2 (Mdm2) (Costa et al., 2013) and the PI3K/AKT/mTOR pathway (Liu et al., 2015) are involved in TMZ resistance mechanisms.”
BackgroundDaniele, S., Pietra, V. L., Barresi, E., Maro, S. D., Pozzo, E. D., Robello, M., Motta, C. L., Cosconati, S., Taliani, S., Marinelli, L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01767 · Cited by 32
Self-citationMDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Chojak, R., Fares, J., Petrosyan, E., & Lesniak, M. S. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04387-3 · Cited by 35
Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells
Daniele, S., Pietrobono, D., Costa, B., Giustiniano, M., Pietra, V. L., Giacomelli, C., Regina, G. L., Silvestri, R., Taliani, S., Trincavelli, M. L., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00023 · Cited by 33
Self-citationRecent advances in the discovery of small molecules targeting glioblastoma
Fernandes, G., Fernandes, B. C., Valente, V., & dos Santos, J. L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.033 · Cited by 29
Daniele, S., Pietrobono, D., Fusi, J., Gerfo, A. L., Cerri, E., Chico, L., Iofrida, C., Petrozzi, L., Baldacci, F., Giacomelli, C., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00017 · Cited by 31
“In brief, platelets (1,8 mg of proteins) were lysed with RIPA buffer (Costa et al., 2013) and then resolved by SDS-PAGE (8.5%).”
InfluentialSelf-citationMerlino, F., Daniele, S., Pietra, V. L., Maro, S. D., Leva, F. S. D., Brancaccio, D., Tomassi, S., Giuntini, S., Cerofolini, L., Fragai, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00004 · Cited by 28
Self-citationTSPO ligand residence time influences human glioblastoma multiforme cell death/life balance
Costa, B., Pozzo, E. D., Giacomelli, C., Taliani, S., Bendinelli, S., Barresi, E., Settimo, F. D., & Martini, C. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1063-3 · Cited by 27
Self-citationGiustiniano, M., Daniele, S., Pelliccia, S., Pietra, V. L., Pietrobono, D., Brancaccio, D., Cosconati, S., Messere, A., Giuntini, S., Cerofolini, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00912 · Cited by 25
Self-citationThiazole Moiety: An Interesting Scaffold for Developing New Antitumoral Compounds
Ramos-Inza, S., Aydillo, C., Sanmartín, C., & Plano, D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82741 · Cited by 29
“Two analogs withstand in this class of compounds: a) ISA27 (Figure 3), which not only presented tumor growth inhibition in vivo alone in a glioblastoma xenograft model but also a synergistic effect with temozolomide, a first-line treatment drug against brain cancers [16], and b) SM13 (Figure 3), an analog that reduced…”
BackgroundHuman Neural Stem Cell Aging Is Counteracted by α-Glycerylphosphorylethanolamine
Daniele, S., Pozzo, E. D., Iofrida, C., & Martini, C. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00078 · Cited by 25
Self-citationReuther, C., Heinzle, V., Nölting, S., Herterich, S., Hahner, S., Halilovic, E., Jeay, S., Wuerthner, J. U., Aristizabal Prada, E. T., Spöttl, G., et al. (2018) · Neuroendocrinology · doi:10.1159/000453369 · Cited by 25
Targeted Therapies for the Treatment of Glioblastoma in Adults
Chuang, D. F., & Lin, X. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0807-1 · Cited by 23
Molecular mechanisms of microRNAs in glioblastoma pathogenesis
Behrooz, A. B., Latifi‐Navid, H., Nezhadi, A., Świat, M., Łoś, M., Jamalpoor, Z., & Ghavami, S. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119482 · Cited by 26
Inferring Network Structure in Non-normal and Mixed Discrete-continuous Genomic Data
Bhadra, A., Rao, A. U. K., & Baladandayuthapani, V. (2017) · Biometrics · doi:10.1111/biom.12711 · Cited by 22
Aissaoui-Zid, D., Saada, M.-C., Moslah, W., Potier‐Cartereau, M., Lemettre, A., Othman, H., Gaysinski, M., Abdelkafi-Koubaa, Z., Souid, S., Marrakchi, N., et al. (2021) · Molecules · doi:10.3390/molecules26247610 · Cited by 23
Lu, S., Lu, K. N., Cheng, S., Hu, B., Ma, X., Nystrom, N. A., & Lu, X. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004257 · Cited by 20
“Inhibition ofMDM2 induces cell apoptosis [54,55] and reactivates p53 in GBM cells, resulting in inhibition of GBM cell growth in vitro and in GBM xenografts in mice[56].”
BackgroundJoint Learning of Multiple Differential Networks With Latent Variables
Ou-Yang, L., Zhang, X.-F., Zhao, X., Wang, D. D., Wang, F. L., Lei, B., & Yan, H. (2018) · IEEE Transactions on Cybernetics · doi:10.1109/tcyb.2018.2845838 · Cited by 23
“MDM2 is a major physiological negative regulator of TP53, and MDM2 oncogene activation may be characteristic as negative prognostic marker of primary glioblastomas [49].”
BackgroundNew small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
Sorriento, D., Giudice, C. D., Bertamino, A., Ciccarelli, M., Gomez-Monterrey, I. M., Campiglia, P., Novellino, E., Illario, M., Trimarco, B., LUCA, N. D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.577 · Cited by 22
“These compounds are able to induce apoptosis of human tumour cell lines both in vitro and in vivo (GomezMonterrey et al, 2010; Bertamino et al, 2013; Costa et al, 2013).”
BackgroundSelf-citationDaniele, S., Giacomelli, C., Pietrobono, D., Barresi, E., Piccarducci, R., Pietra, V. L., Taliani, S., Settimo, F. D., Marinelli, L., Novellino, E., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.01.012 · Cited by 18
Self-citationDaniele, S., Barresi, E., Zappelli, E., Marinelli, L., Novellino, E., Settimo, F. D., Taliani, S., Trincavelli, M. L., & Martini, C. (2016) · Oncotarget · doi:10.18632/oncotarget.6872 · Cited by 19
“P53 is negatively regulated by the murine double minute 2 (MDM2), and inhibitors of MDM2/p53 interaction currently represent another viable approach in GBM therapy [22-24].”
Self-citationPost-Transcriptional Modifications of RNA as Regulators of Apoptosis in Glioblastoma
Dome, A. S., Dymova, M. A., Richter, V. A., & Stepanov, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169272 · Cited by 16
Wang, H., Liu, D., & Yang, J. (2019) · Neoplasma · doi:10.4149/neo_2018_181008n746 · Cited by 18
“as a reasonable approach for GBM treatment [45, 46].”
Azam, Z., Quillien, V., Wang, G., & To, S.-S. T. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1551621 · Cited by 15
“Genetic changes vary in GB, for example, IDH1 mutation is evident in secondary GB only [4] and p53 mutations are more common in secondary GB than primary [5].”
BackgroundAn Effective Virtual Screening Protocol To Identify Promising p53–MDM2 Inhibitors
Tortorella, P., Laghezza, A., Durante, M., Gomez-Monterrey, I. M., Bertamino, A., Campiglia, P., Loiodice, F., Daniele, S., Martini, C., & Agamennone, M. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00747 · Cited by 12
Self-citationClinical Targeting of Altered Metabolism in High-Grade Glioma
Scott, A. J., Lyssiotis, C. A., & Wahl, D. R. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000550 · Cited by 12
Ngadiono, E., & Hardiany, N. S. (2019) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2019.26.4.2 · Cited by 11
Evaluation of JC and Cytomegalo Viruses in Glioblastoma Tissue
Afshar, R. M., Mollaei, H. R., Zandi, B., & Iranpour, M. (2016) · PubMed Central · doi:10.22034/apjcp.2016.17.11.4907 · Cited by 12
“Several CMV proteins interact and inactivate proteins of the Rb family (Retinoblastoma) as well as p53, resulting functions of p53 and Rb were down-regulate (Costa et al., 2013) .”
BackgroundYang, K., Jung, S. W., Shin, H., Lim, D. H., Lee, J.-I., Kong, D., Seol, H. J., Kim, S. T., & Nam, D. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.11.025 · Cited by 10
p53/E2F1/miR-25 axis regulates apoptosis induction in glioblastoma cells: a qualitative model
Silveira, D. A., Gupta, S., & Mombach, J. C. M. (2020) · Journal of Physics Complexity · doi:10.1088/2632-072x/aba3bb · Cited by 7
Jackson, L. R., Masi, M. R., Selman, B., Sandusky, G. E., Zarrinmayeh, H., DAS, S. K., Maharjan, S., Wang, N., Zheng, Q., Pollok, K. E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939260 · Cited by 5
de Almeida, J. F. M., Contestabile, M., Tonazzini, I., Cesari, C. D., Baroncelli, L., Martini, C., & Daniele, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211032 · Cited by 4
“Sequences and annealing temperatures have been reported before [51].”
Self-citationExploring the therapeutic role of carnosol in cancer: from molecular insights to clinical promise
Nakhaei, A., Afshari, S., Omidkhoda, A., Mohtashami, E., Vahedi, M. M., Ahmadi, S. S., Jalali, M., & Afshari, A. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02959-z · Cited by 4
“Despite the presence of wild-type p53, the functional efficacy of this tumor suppressor protein is compromised due to the overexpression of its physiological inhibitor MDM2 [70, 119, 120].”
Nuti, E., Pietra, V. L., Daniele, S., Cuffaro, D., Ciccone, L., Giacomelli, C., Cason, C., Carotenuto, A., D’Amore, V. M., Pozzo, E. D., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111318 · Cited by 3
“In particular, the activation of the cyclin-dependent kinase (CDK) inhibitor p21 (also known as p21WAF1/Cip1) caused the cell cycle arrest at both G1 and G2 phases [30,32].”
BackgroundMethodResultSelf-citationNakano, H., KIDACHI, J., IMAZATO, M., KOJIMA, M., & Tsutsumi, K. (2025) · Biomedical Research · doi:10.2220/biomedres.46.101 · Cited by 1
Yang, Y., Tang, N., Liu, Y., Choi, W., Kim, J. H., Kim, H. G., Yu, T., & Cho, J. Y. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111252 · Cited by 1
Ahmed, S. I., Bareeqa, S. B., & Samar, S. S. (2018) · Cureus · doi:10.7759/cureus.3034 · Cited by 1
“This resulted in an effective antagonism for MDM-2 molecules [1].”
BackgroundLu, S., Lu, K. G., Cheng, S., Hu, B., Ma, X., Nystrom, N. A., & Lu, X. (2015) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2015.7359942 · Cited by 1
Apoptosis Pathways and Chemotherapy in Brain Tumors
Venere, M., De, K., Yoo, J. Y., & Kaur, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00020-6
Harisankar, A. (2018) · Figshare · Cited by 1
Karges, J. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7034
Pharmacokinetic Study of Novel Anthraquinone Analogues
Guo, Y. (2019)
Bicyclic 5–5 Systems With One Bridgehead (Ring Junction) Nitrogen Atom: One Extra Heteroatom 1:0
González‐Zamora, E., & Islas‐Jácome, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818655-8.00029-9
Cell death pathways and chemotherapy in brain tumors
Sahu, U., Venere, M., & Kaur, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00026-7
Mécanismes et implications thérapeutiques de l'hypermutation dans les gliomes
Touat, M. (2020) · theses.fr (ABES) · doi:10.70675/3cf296c0z53a7z446dz8927zbeeea7661f6a
Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications
Lamrabet, S., Houssaini, A. S., Bennis, S., & Hassani, R. A. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177940
BindingDB (2021) · UC San Diego · doi:10.7270/q20r9svb
Metadata
- Authors
- Costa, B., Bendinelli, S., Gabelloni, P., Da Pozzo, E., Daniele, S., Scatena, F., Vanacore, R., Campiglia, P., Bertamino, A., Gomez-Monterrey, I., Sorriento, D., Del Giudice, C., Iaccarino, G., Novellino, E., & Martini, C.
- Affiliations
- University of Pisa (IT)
- Ospedale Cisanello (IT)
- University of Salerno (IT)
- University of Naples Federico II (IT)
- Corresponding author
- Costa, Barbara
- Martini, Claudia
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-19
- Volume
- 8
- Issue
- 8
- Pages
- e72281
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3747081
- OpenAlex
- W1999920903
- Cited by
- 79
- References
- 53
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 9 · 2018: 12 · 2017: 10 · 2016: 11 · 2015: 6 · 2014: 4
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- glioblastoma, MDM2 inhibitors, p53 reactivation, temozolomide combination therapy, apoptosis, cell cycle arrest, tumor xenografts, small molecule inhibitors, chemoresistance
- MeSH terms
- Animals, Antineoplastic Agents, Brain Neoplasms, Female, Glioblastoma, Humans, Indoles, Mice, Inbred BALB C, Mice, Nude, Protein Binding, Spiro Compounds, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Tumor Burden, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.